0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Hepatocellular Carcinoma Drug Market Insights, Forecast to 2028
Published Date: February 2022
|
Report Code: QYRE-Othe-0100
Home | Market Reports | Business & Industrial | Pharmaceuticals & Biotech
Global Hepatocellular Carcinoma Drug Market Insights Forecast to 2028

Global Hepatocellular Carcinoma Drug Market Insights, Forecast to 2028

Code: QYRE-Othe-0100
Report
February 2022
109 Pages
QYResearch
Region: Global,
Description
Table of Content
Tables & Figures
Hepatocellular Carcinoma Drug is a drug for treating Hepatocellular Carcinoma.
Market Analysis and Insights: Global Hepatocellular Carcinoma Drug Market

Due to the COVID-19 pandemic, the global Hepatocellular Carcinoma Drug market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period.

Fully considering the economic change by this health crisis, Chemotherapy accounting for % of the Hepatocellular Carcinoma Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.

While Surgical Resection segment is altered to an % CAGR throughout this forecast period.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for Hepatocellular Carcinoma Drug in US$ by following Product Segments.: Chemotherapy, Brachytherapy and Ablation Therapy.
Company profiles are primarily based on public domain information including company
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
Global Hepatocellular Carcinoma Drug Scope and Segment
Hepatocellular Carcinoma Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Hepatocellular Carcinoma Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

Chemotherapy
Brachytherapy
Ablation Therapy

Segment by Application

Surgical Resection
Liver Transplantation
Ablation

BY COMPANY

Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm

BY REGION

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
1 Study Coverage
1.1 Hepatocellular Carcinoma Drug Product Introduction
1.2 Market by Type
1.2.1 Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Chemotherapy
1.2.3 Brachytherapy
1.2.4 Ablation Therapy
1.3 Market by Application
1.3.1 Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Surgical Resection
1.3.3 Liver Transplantation
1.3.4 Ablation
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Hepatocellular Carcinoma Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Hepatocellular Carcinoma Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Hepatocellular Carcinoma Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Hepatocellular Carcinoma Drug Sales by Region
2.4.1 Global Hepatocellular Carcinoma Drug Sales by Region (2017-2022)
2.4.2 Global Sales Hepatocellular Carcinoma Drug by Region (2023-2028)
2.5 Global Hepatocellular Carcinoma Drug Revenue by Region
2.5.1 Global Hepatocellular Carcinoma Drug Revenue by Region (2017-2022)
2.5.2 Global Hepatocellular Carcinoma Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Hepatocellular Carcinoma Drug Sales by Manufacturers
3.1.1 Global Top Hepatocellular Carcinoma Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Hepatocellular Carcinoma Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Hepatocellular Carcinoma Drug in 2021
3.2 Global Hepatocellular Carcinoma Drug Revenue by Manufacturers
3.2.1 Global Hepatocellular Carcinoma Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Hepatocellular Carcinoma Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Hepatocellular Carcinoma Drug Revenue in 2021
3.3 Global Hepatocellular Carcinoma Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Hepatocellular Carcinoma Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Hepatocellular Carcinoma Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Hepatocellular Carcinoma Drug Sales by Type
4.1.1 Global Hepatocellular Carcinoma Drug Historical Sales by Type (2017-2022)
4.1.2 Global Hepatocellular Carcinoma Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Hepatocellular Carcinoma Drug Sales Market Share by Type (2017-2028)
4.2 Global Hepatocellular Carcinoma Drug Revenue by Type
4.2.1 Global Hepatocellular Carcinoma Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Hepatocellular Carcinoma Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Hepatocellular Carcinoma Drug Revenue Market Share by Type (2017-2028)
4.3 Global Hepatocellular Carcinoma Drug Price by Type
4.3.1 Global Hepatocellular Carcinoma Drug Price by Type (2017-2022)
4.3.2 Global Hepatocellular Carcinoma Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Hepatocellular Carcinoma Drug Sales by Application
5.1.1 Global Hepatocellular Carcinoma Drug Historical Sales by Application (2017-2022)
5.1.2 Global Hepatocellular Carcinoma Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Hepatocellular Carcinoma Drug Sales Market Share by Application (2017-2028)
5.2 Global Hepatocellular Carcinoma Drug Revenue by Application
5.2.1 Global Hepatocellular Carcinoma Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Hepatocellular Carcinoma Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Hepatocellular Carcinoma Drug Revenue Market Share by Application (2017-2028)
5.3 Global Hepatocellular Carcinoma Drug Price by Application
5.3.1 Global Hepatocellular Carcinoma Drug Price by Application (2017-2022)
5.3.2 Global Hepatocellular Carcinoma Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Hepatocellular Carcinoma Drug Market Size by Type
6.1.1 North America Hepatocellular Carcinoma Drug Sales by Type (2017-2028)
6.1.2 North America Hepatocellular Carcinoma Drug Revenue by Type (2017-2028)
6.2 North America Hepatocellular Carcinoma Drug Market Size by Application
6.2.1 North America Hepatocellular Carcinoma Drug Sales by Application (2017-2028)
6.2.2 North America Hepatocellular Carcinoma Drug Revenue by Application (2017-2028)
6.3 North America Hepatocellular Carcinoma Drug Market Size by Country
6.3.1 North America Hepatocellular Carcinoma Drug Sales by Country (2017-2028)
6.3.2 North America Hepatocellular Carcinoma Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Hepatocellular Carcinoma Drug Market Size by Type
7.1.1 Europe Hepatocellular Carcinoma Drug Sales by Type (2017-2028)
7.1.2 Europe Hepatocellular Carcinoma Drug Revenue by Type (2017-2028)
7.2 Europe Hepatocellular Carcinoma Drug Market Size by Application
7.2.1 Europe Hepatocellular Carcinoma Drug Sales by Application (2017-2028)
7.2.2 Europe Hepatocellular Carcinoma Drug Revenue by Application (2017-2028)
7.3 Europe Hepatocellular Carcinoma Drug Market Size by Country
7.3.1 Europe Hepatocellular Carcinoma Drug Sales by Country (2017-2028)
7.3.2 Europe Hepatocellular Carcinoma Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Hepatocellular Carcinoma Drug Market Size by Type
8.1.1 Asia Pacific Hepatocellular Carcinoma Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Hepatocellular Carcinoma Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Hepatocellular Carcinoma Drug Market Size by Application
8.2.1 Asia Pacific Hepatocellular Carcinoma Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Hepatocellular Carcinoma Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Hepatocellular Carcinoma Drug Market Size by Region
8.3.1 Asia Pacific Hepatocellular Carcinoma Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Hepatocellular Carcinoma Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Hepatocellular Carcinoma Drug Market Size by Type
9.1.1 Latin America Hepatocellular Carcinoma Drug Sales by Type (2017-2028)
9.1.2 Latin America Hepatocellular Carcinoma Drug Revenue by Type (2017-2028)
9.2 Latin America Hepatocellular Carcinoma Drug Market Size by Application
9.2.1 Latin America Hepatocellular Carcinoma Drug Sales by Application (2017-2028)
9.2.2 Latin America Hepatocellular Carcinoma Drug Revenue by Application (2017-2028)
9.3 Latin America Hepatocellular Carcinoma Drug Market Size by Country
9.3.1 Latin America Hepatocellular Carcinoma Drug Sales by Country (2017-2028)
9.3.2 Latin America Hepatocellular Carcinoma Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Hepatocellular Carcinoma Drug Market Size by Type
10.1.1 Middle East and Africa Hepatocellular Carcinoma Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Hepatocellular Carcinoma Drug Market Size by Application
10.2.1 Middle East and Africa Hepatocellular Carcinoma Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Hepatocellular Carcinoma Drug Market Size by Country
10.3.1 Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Corporation Information
11.1.2 Johnson & Johnson Overview
11.1.3 Johnson & Johnson Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Johnson & Johnson Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Johnson & Johnson Recent Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Corporation Information
11.2.2 Gilead Sciences Overview
11.2.3 Gilead Sciences Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Gilead Sciences Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Gilead Sciences Recent Developments
11.3 Pacira
11.3.1 Pacira Corporation Information
11.3.2 Pacira Overview
11.3.3 Pacira Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Pacira Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Pacira Recent Developments
11.4 Sun Pharmaceutical
11.4.1 Sun Pharmaceutical Corporation Information
11.4.2 Sun Pharmaceutical Overview
11.4.3 Sun Pharmaceutical Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Sun Pharmaceutical Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Sun Pharmaceutical Recent Developments
11.5 Luye Pharma
11.5.1 Luye Pharma Corporation Information
11.5.2 Luye Pharma Overview
11.5.3 Luye Pharma Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Luye Pharma Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Luye Pharma Recent Developments
11.6 Sigma-Tau Group
11.6.1 Sigma-Tau Group Corporation Information
11.6.2 Sigma-Tau Group Overview
11.6.3 Sigma-Tau Group Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Sigma-Tau Group Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Sigma-Tau Group Recent Developments
11.7 Fudan-Zhangjiang
11.7.1 Fudan-Zhangjiang Corporation Information
11.7.2 Fudan-Zhangjiang Overview
11.7.3 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Fudan-Zhangjiang Recent Developments
11.8 Teva Pharmaceutical
11.8.1 Teva Pharmaceutical Corporation Information
11.8.2 Teva Pharmaceutical Overview
11.8.3 Teva Pharmaceutical Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Teva Pharmaceutical Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Teva Pharmaceutical Recent Developments
11.9 CSPC
11.9.1 CSPC Corporation Information
11.9.2 CSPC Overview
11.9.3 CSPC Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 CSPC Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 CSPC Recent Developments
11.10 Novartis
11.10.1 Novartis Corporation Information
11.10.2 Novartis Overview
11.10.3 Novartis Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Novartis Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Novartis Recent Developments
11.11 Kingond Pharm
11.11.1 Kingond Pharm Corporation Information
11.11.2 Kingond Pharm Overview
11.11.3 Kingond Pharm Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Kingond Pharm Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Kingond Pharm Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Hepatocellular Carcinoma Drug Industry Chain Analysis
12.2 Hepatocellular Carcinoma Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Hepatocellular Carcinoma Drug Production Mode & Process
12.4 Hepatocellular Carcinoma Drug Sales and Marketing
12.4.1 Hepatocellular Carcinoma Drug Sales Channels
12.4.2 Hepatocellular Carcinoma Drug Distributors
12.5 Hepatocellular Carcinoma Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Hepatocellular Carcinoma Drug Industry Trends
13.2 Hepatocellular Carcinoma Drug Market Drivers
13.3 Hepatocellular Carcinoma Drug Market Challenges
13.4 Hepatocellular Carcinoma Drug Market Restraints
14 Key Findings in The Global Hepatocellular Carcinoma Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
    Table 1. Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Chemotherapy
    Table 3. Major Manufacturers of Brachytherapy
    Table 4. Major Manufacturers of Ablation Therapy
    Table 5. Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 6. Global Hepatocellular Carcinoma Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 7. Global Hepatocellular Carcinoma Drug Sales by Region (2017-2022) & (K Units)
    Table 8. Global Hepatocellular Carcinoma Drug Sales Market Share by Region (2017-2022)
    Table 9. Global Hepatocellular Carcinoma Drug Sales by Region (2023-2028) & (K Units)
    Table 10. Global Hepatocellular Carcinoma Drug Sales Market Share by Region (2023-2028)
    Table 11. Global Hepatocellular Carcinoma Drug Revenue by Region (2017-2022) & (US$ Million)
    Table 12. Global Hepatocellular Carcinoma Drug Revenue Market Share by Region (2017-2022)
    Table 13. Global Hepatocellular Carcinoma Drug Revenue by Region (2023-2028) & (US$ Million)
    Table 14. Global Hepatocellular Carcinoma Drug Revenue Market Share by Region (2023-2028)
    Table 15. Global Hepatocellular Carcinoma Drug Sales by Manufacturers (2017-2022) & (K Units)
    Table 16. Global Hepatocellular Carcinoma Drug Sales Share by Manufacturers (2017-2022)
    Table 17. Global Hepatocellular Carcinoma Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 18. Global Hepatocellular Carcinoma Drug Revenue Share by Manufacturers (2017-2022)
    Table 19. Hepatocellular Carcinoma Drug Price by Manufacturers (2017-2022) &(USD/Unit)
    Table 20. Global Hepatocellular Carcinoma Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 21. Global Hepatocellular Carcinoma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocellular Carcinoma Drug as of 2021)
    Table 22. Hepatocellular Carcinoma Drug Manufacturing Base Distribution and Headquarters
    Table 23. Manufacturers Hepatocellular Carcinoma Drug Product Offered
    Table 24. Date of Manufacturers Enter into Hepatocellular Carcinoma Drug Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Hepatocellular Carcinoma Drug Sales by Type (2017-2022) & (K Units)
    Table 27. Global Hepatocellular Carcinoma Drug Sales by Type (2023-2028) & (K Units)
    Table 28. Global Hepatocellular Carcinoma Drug Sales Share by Type (2017-2022)
    Table 29. Global Hepatocellular Carcinoma Drug Sales Share by Type (2023-2028)
    Table 30. Global Hepatocellular Carcinoma Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 31. Global Hepatocellular Carcinoma Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 32. Global Hepatocellular Carcinoma Drug Revenue Share by Type (2017-2022)
    Table 33. Global Hepatocellular Carcinoma Drug Revenue Share by Type (2023-2028)
    Table 34. Hepatocellular Carcinoma Drug Price by Type (2017-2022) & (USD/Unit)
    Table 35. Global Hepatocellular Carcinoma Drug Price Forecast by Type (2023-2028) & (USD/Unit)
    Table 36. Global Hepatocellular Carcinoma Drug Sales by Application (2017-2022) & (K Units)
    Table 37. Global Hepatocellular Carcinoma Drug Sales by Application (2023-2028) & (K Units)
    Table 38. Global Hepatocellular Carcinoma Drug Sales Share by Application (2017-2022)
    Table 39. Global Hepatocellular Carcinoma Drug Sales Share by Application (2023-2028)
    Table 40. Global Hepatocellular Carcinoma Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 41. Global Hepatocellular Carcinoma Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 42. Global Hepatocellular Carcinoma Drug Revenue Share by Application (2017-2022)
    Table 43. Global Hepatocellular Carcinoma Drug Revenue Share by Application (2023-2028)
    Table 44. Hepatocellular Carcinoma Drug Price by Application (2017-2022) & (USD/Unit)
    Table 45. Global Hepatocellular Carcinoma Drug Price Forecast by Application (2023-2028) & (USD/Unit)
    Table 46. North America Hepatocellular Carcinoma Drug Sales by Type (2017-2022) & (K Units)
    Table 47. North America Hepatocellular Carcinoma Drug Sales by Type (2023-2028) & (K Units)
    Table 48. North America Hepatocellular Carcinoma Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 49. North America Hepatocellular Carcinoma Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 50. North America Hepatocellular Carcinoma Drug Sales by Application (2017-2022) & (K Units)
    Table 51. North America Hepatocellular Carcinoma Drug Sales by Application (2023-2028) & (K Units)
    Table 52. North America Hepatocellular Carcinoma Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 53. North America Hepatocellular Carcinoma Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 54. North America Hepatocellular Carcinoma Drug Sales by Country (2017-2022) & (K Units)
    Table 55. North America Hepatocellular Carcinoma Drug Sales by Country (2023-2028) & (K Units)
    Table 56. North America Hepatocellular Carcinoma Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 57. North America Hepatocellular Carcinoma Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 58. Europe Hepatocellular Carcinoma Drug Sales by Type (2017-2022) & (K Units)
    Table 59. Europe Hepatocellular Carcinoma Drug Sales by Type (2023-2028) & (K Units)
    Table 60. Europe Hepatocellular Carcinoma Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 61. Europe Hepatocellular Carcinoma Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 62. Europe Hepatocellular Carcinoma Drug Sales by Application (2017-2022) & (K Units)
    Table 63. Europe Hepatocellular Carcinoma Drug Sales by Application (2023-2028) & (K Units)
    Table 64. Europe Hepatocellular Carcinoma Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 65. Europe Hepatocellular Carcinoma Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 66. Europe Hepatocellular Carcinoma Drug Sales by Country (2017-2022) & (K Units)
    Table 67. Europe Hepatocellular Carcinoma Drug Sales by Country (2023-2028) & (K Units)
    Table 68. Europe Hepatocellular Carcinoma Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 69. Europe Hepatocellular Carcinoma Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 70. Asia Pacific Hepatocellular Carcinoma Drug Sales by Type (2017-2022) & (K Units)
    Table 71. Asia Pacific Hepatocellular Carcinoma Drug Sales by Type (2023-2028) & (K Units)
    Table 72. Asia Pacific Hepatocellular Carcinoma Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 73. Asia Pacific Hepatocellular Carcinoma Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 74. Asia Pacific Hepatocellular Carcinoma Drug Sales by Application (2017-2022) & (K Units)
    Table 75. Asia Pacific Hepatocellular Carcinoma Drug Sales by Application (2023-2028) & (K Units)
    Table 76. Asia Pacific Hepatocellular Carcinoma Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 77. Asia Pacific Hepatocellular Carcinoma Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 78. Asia Pacific Hepatocellular Carcinoma Drug Sales by Region (2017-2022) & (K Units)
    Table 79. Asia Pacific Hepatocellular Carcinoma Drug Sales by Region (2023-2028) & (K Units)
    Table 80. Asia Pacific Hepatocellular Carcinoma Drug Revenue by Region (2017-2022) & (US$ Million)
    Table 81. Asia Pacific Hepatocellular Carcinoma Drug Revenue by Region (2023-2028) & (US$ Million)
    Table 82. Latin America Hepatocellular Carcinoma Drug Sales by Type (2017-2022) & (K Units)
    Table 83. Latin America Hepatocellular Carcinoma Drug Sales by Type (2023-2028) & (K Units)
    Table 84. Latin America Hepatocellular Carcinoma Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 85. Latin America Hepatocellular Carcinoma Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 86. Latin America Hepatocellular Carcinoma Drug Sales by Application (2017-2022) & (K Units)
    Table 87. Latin America Hepatocellular Carcinoma Drug Sales by Application (2023-2028) & (K Units)
    Table 88. Latin America Hepatocellular Carcinoma Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 89. Latin America Hepatocellular Carcinoma Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 90. Latin America Hepatocellular Carcinoma Drug Sales by Country (2017-2022) & (K Units)
    Table 91. Latin America Hepatocellular Carcinoma Drug Sales by Country (2023-2028) & (K Units)
    Table 92. Latin America Hepatocellular Carcinoma Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 93. Latin America Hepatocellular Carcinoma Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 94. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Type (2017-2022) & (K Units)
    Table 95. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Type (2023-2028) & (K Units)
    Table 96. Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 97. Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 98. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Application (2017-2022) & (K Units)
    Table 99. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Application (2023-2028) & (K Units)
    Table 100. Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 101. Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 102. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country (2017-2022) & (K Units)
    Table 103. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country (2023-2028) & (K Units)
    Table 104. Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 105. Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 106. Johnson & Johnson Corporation Information
    Table 107. Johnson & Johnson Description and Major Businesses
    Table 108. Johnson & Johnson Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 109. Johnson & Johnson Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 110. Johnson & Johnson Recent Developments
    Table 111. Gilead Sciences Corporation Information
    Table 112. Gilead Sciences Description and Major Businesses
    Table 113. Gilead Sciences Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 114. Gilead Sciences Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 115. Gilead Sciences Recent Developments
    Table 116. Pacira Corporation Information
    Table 117. Pacira Description and Major Businesses
    Table 118. Pacira Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 119. Pacira Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 120. Pacira Recent Developments
    Table 121. Sun Pharmaceutical Corporation Information
    Table 122. Sun Pharmaceutical Description and Major Businesses
    Table 123. Sun Pharmaceutical Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 124. Sun Pharmaceutical Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 125. Sun Pharmaceutical Recent Developments
    Table 126. Luye Pharma Corporation Information
    Table 127. Luye Pharma Description and Major Businesses
    Table 128. Luye Pharma Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 129. Luye Pharma Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 130. Luye Pharma Recent Developments
    Table 131. Sigma-Tau Group Corporation Information
    Table 132. Sigma-Tau Group Description and Major Businesses
    Table 133. Sigma-Tau Group Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 134. Sigma-Tau Group Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 135. Sigma-Tau Group Recent Developments
    Table 136. Fudan-Zhangjiang Corporation Information
    Table 137. Fudan-Zhangjiang Description and Major Businesses
    Table 138. Fudan-Zhangjiang Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 139. Fudan-Zhangjiang Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 140. Fudan-Zhangjiang Recent Developments
    Table 141. Teva Pharmaceutical Corporation Information
    Table 142. Teva Pharmaceutical Description and Major Businesses
    Table 143. Teva Pharmaceutical Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 144. Teva Pharmaceutical Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 145. Teva Pharmaceutical Recent Developments
    Table 146. CSPC Corporation Information
    Table 147. CSPC Description and Major Businesses
    Table 148. CSPC Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 149. CSPC Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 150. CSPC Recent Developments
    Table 151. Novartis Corporation Information
    Table 152. Novartis Description and Major Businesses
    Table 153. Novartis Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 154. Novartis Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 155. Novartis Recent Developments
    Table 156. Kingond Pharm Corporation Information
    Table 157. Kingond Pharm Description and Major Businesses
    Table 158. Kingond Pharm Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 159. Kingond Pharm Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 160. Kingond Pharm Recent Developments
    Table 161. Key Raw Materials Lists
    Table 162. Raw Materials Key Suppliers Lists
    Table 163. Hepatocellular Carcinoma Drug Distributors List
    Table 164. Hepatocellular Carcinoma Drug Customers List
    Table 165. Hepatocellular Carcinoma Drug Market Trends
    Table 166. Hepatocellular Carcinoma Drug Market Drivers
    Table 167. Hepatocellular Carcinoma Drug Market Challenges
    Table 168. Hepatocellular Carcinoma Drug Market Restraints
    Table 169. Research Programs/Design for This Report
    Table 170. Key Data Information from Secondary Sources
    Table 171. Key Data Information from Primary Sources
List of Figures
    Figure 1. Hepatocellular Carcinoma Drug Product Picture
    Figure 3. Global Hepatocellular Carcinoma Drug Market Share by Type in 2021 & 2028
    Figure 3. Chemotherapy Product Picture
    Figure 4. Brachytherapy Product Picture
    Figure 5. Ablation Therapy Product Picture
    Figure 6. Global Hepatocellular Carcinoma Drug Market Share by Application in 2021 & 2028
    Figure 7. Surgical Resection
    Figure 8. Liver Transplantation
    Figure 9. Ablation
    Figure 10. Hepatocellular Carcinoma Drug Report Years Considered
    Figure 11. Global Hepatocellular Carcinoma Drug Sales 2017-2028 (K Units)
    Figure 12. Global Hepatocellular Carcinoma Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Hepatocellular Carcinoma Drug Revenue 2017-2028 (US$ Million)
    Figure 14. Global Hepatocellular Carcinoma Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 15. Global Hepatocellular Carcinoma Drug Sales Market Share by Region (2017-2022)
    Figure 16. Global Hepatocellular Carcinoma Drug Sales Market Share by Region (2023-2028)
    Figure 17. North America Hepatocellular Carcinoma Drug Sales YoY (2017-2028) & (K Units)
    Figure 18. North America Hepatocellular Carcinoma Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 19. Europe Hepatocellular Carcinoma Drug Sales YoY (2017-2028) & (K Units)
    Figure 20. Europe Hepatocellular Carcinoma Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 21. Asia-Pacific Hepatocellular Carcinoma Drug Sales YoY (2017-2028) & (K Units)
    Figure 22. Asia-Pacific Hepatocellular Carcinoma Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 23. Latin America Hepatocellular Carcinoma Drug Sales YoY (2017-2028) & (K Units)
    Figure 24. Latin America Hepatocellular Carcinoma Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 25. Middle East & Africa Hepatocellular Carcinoma Drug Sales YoY (2017-2028) & (K Units)
    Figure 26. Middle East & Africa Hepatocellular Carcinoma Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 27. The Hepatocellular Carcinoma Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 28. The Top 5 and 10 Largest Manufacturers of Hepatocellular Carcinoma Drug in the World: Market Share by Hepatocellular Carcinoma Drug Revenue in 2021
    Figure 29. Global Hepatocellular Carcinoma Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 30. Global Hepatocellular Carcinoma Drug Sales Market Share by Type (2017-2028)
    Figure 31. Global Hepatocellular Carcinoma Drug Revenue Market Share by Type (2017-2028)
    Figure 32. Global Hepatocellular Carcinoma Drug Sales Market Share by Application (2017-2028)
    Figure 33. Global Hepatocellular Carcinoma Drug Revenue Market Share by Application (2017-2028)
    Figure 34. North America Hepatocellular Carcinoma Drug Sales Market Share by Type (2017-2028)
    Figure 35. North America Hepatocellular Carcinoma Drug Revenue Market Share by Type (2017-2028)
    Figure 36. North America Hepatocellular Carcinoma Drug Sales Market Share by Application (2017-2028)
    Figure 37. North America Hepatocellular Carcinoma Drug Revenue Market Share by Application (2017-2028)
    Figure 38. North America Hepatocellular Carcinoma Drug Sales Share by Country (2017-2028)
    Figure 39. North America Hepatocellular Carcinoma Drug Revenue Share by Country (2017-2028)
    Figure 40. U.S. Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 41. Canada Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 42. Europe Hepatocellular Carcinoma Drug Sales Market Share by Type (2017-2028)
    Figure 43. Europe Hepatocellular Carcinoma Drug Revenue Market Share by Type (2017-2028)
    Figure 44. Europe Hepatocellular Carcinoma Drug Sales Market Share by Application (2017-2028)
    Figure 45. Europe Hepatocellular Carcinoma Drug Revenue Market Share by Application (2017-2028)
    Figure 46. Europe Hepatocellular Carcinoma Drug Sales Share by Country (2017-2028)
    Figure 47. Europe Hepatocellular Carcinoma Drug Revenue Share by Country (2017-2028)
    Figure 48. Germany Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 49. France Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 50. U.K. Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 51. Italy Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 52. Russia Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 53. Asia Pacific Hepatocellular Carcinoma Drug Sales Market Share by Type (2017-2028)
    Figure 54. Asia Pacific Hepatocellular Carcinoma Drug Revenue Market Share by Type (2017-2028)
    Figure 55. Asia Pacific Hepatocellular Carcinoma Drug Sales Market Share by Application (2017-2028)
    Figure 56. Asia Pacific Hepatocellular Carcinoma Drug Revenue Market Share by Application (2017-2028)
    Figure 57. Asia Pacific Hepatocellular Carcinoma Drug Sales Share by Region (2017-2028)
    Figure 58. Asia Pacific Hepatocellular Carcinoma Drug Revenue Share by Region (2017-2028)
    Figure 59. China Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 60. Japan Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 61. South Korea Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 62. India Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 63. Australia Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 64. Taiwan Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 65. Indonesia Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 66. Thailand Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 67. Malaysia Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 68. Philippines Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 69. Latin America Hepatocellular Carcinoma Drug Sales Market Share by Type (2017-2028)
    Figure 70. Latin America Hepatocellular Carcinoma Drug Revenue Market Share by Type (2017-2028)
    Figure 71. Latin America Hepatocellular Carcinoma Drug Sales Market Share by Application (2017-2028)
    Figure 72. Latin America Hepatocellular Carcinoma Drug Revenue Market Share by Application (2017-2028)
    Figure 73. Latin America Hepatocellular Carcinoma Drug Sales Share by Country (2017-2028)
    Figure 74. Latin America Hepatocellular Carcinoma Drug Revenue Share by Country (2017-2028)
    Figure 75. Mexico Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 76. Brazil Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 77. Argentina Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 78. Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share by Type (2017-2028)
    Figure 79. Middle East and Africa Hepatocellular Carcinoma Drug Revenue Market Share by Type (2017-2028)
    Figure 80. Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share by Application (2017-2028)
    Figure 81. Middle East and Africa Hepatocellular Carcinoma Drug Revenue Market Share by Application (2017-2028)
    Figure 82. Middle East and Africa Hepatocellular Carcinoma Drug Sales Share by Country (2017-2028)
    Figure 83. Middle East and Africa Hepatocellular Carcinoma Drug Revenue Share by Country (2017-2028)
    Figure 84. Turkey Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 85. Saudi Arabia Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 86. U.A.E Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)
    Figure 87. Hepatocellular Carcinoma Drug Value Chain
    Figure 88. Hepatocellular Carcinoma Drug Production Process
    Figure 89. Channels of Distribution
    Figure 90. Distributors Profiles
    Figure 91. Bottom-up and Top-down Approaches for This Report
    Figure 92. Data Triangulation
    Figure 93. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$4900
This license allows only one user to access the PDF.

Electronic (PDF)
$7350
This license allows multiple user to access the PDF.

Electronic (PDF)
$9800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano Dimension

RELATED REPORTS

Global Barium Titanium Oxide Market Insights Forecast to 2028
Global Barium Titanium Oxide Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-9Z7409
Wed May 18 00:00:00 UTC 2022

Add to Cart

Global Aspetic Negative Pressure Pharmaceutical Isolators Market Insights Forecast to 2028
Global Aspetic Negative Pressure Pharmaceutical Isolators Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-0T7466
Fri May 13 00:00:00 UTC 2022

Add to Cart

Global Chemical API Market Insights and Forecast to 2028
Global Chemical API Market Insights and Forecast to 2028

Market Analysis and Insights Global Chemical API MarketThe global Chemical API market size is projected to reach US million by 2028 from US million in 2021 at a CAGR of during 20222028.Fully considering the economic change by this health crisis Bulk API accounting for of the Chemical API global market in 2021 is projected to value US million by 2028 growing at a revised CAGR in the postCOVID19 period.

120 Pages
Type: Report
Code: QYRE-Auto-28A10066
Tue May 03 00:00:00 UTC 2022

Add to Cart